Changes in Circulating Tumor DNA Reflect Clinical Benefit Across Multiple Studies of Patients With Non-Small-Cell Lung Cancer Treated With Immune Checkpoint Inhibitors.
Diana Merino VegaKatherine K NishimuraNévine ZariffaJeffrey C ThompsonAntje HoeringVanessa CilentoAdam RosenthalValsamo AnagnostouJonathan BadenJulia A BeaverAadel A ChaudhuriDarya ChudovaAlexander D FineJoseph FioreRachel HodgeDarren HodgsonNathan HunkapillerDaniel M KlassJulie KobieCarol PeñaGene A PennelloNeil PetermanReena PhilipKatie J QuinnDavid RabenGary L RosnerMark SausenAyse TezcanQi XiaJing YiAmanda G YoungMark D StewartErica L CarpenterCharu AggarwalJeff AllenPublished in: JCO precision oncology (2022)
In this pooled analysis of five independent clinical trials, consistent and robust associations between reductions in ctDNA and outcomes were found across multiple end points assessed in patients with non-small-cell lung cancer treated with an ICI. Additional tumor types, stages, and drug classes should be included in future analyses to further validate this. CtDNA may serve as an important tool in clinical development and an early indicator of treatment benefit.